Adaptimmune Therapeutics plc
ADAP
$0.0569
-$0.0016-2.74%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 36.24% | 35.88% | -321.27% | -125.34% | 243.33% |
| Total Depreciation and Amortization | 1.74% | -13.02% | 0.60% | 2.77% | -3.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 719.20% | -101.07% | 97.91% | 136.12% | -26.03% |
| Change in Net Operating Assets | 63.83% | -183.57% | 156.11% | -66.45% | -364.08% |
| Cash from Operations | 47.77% | -94.69% | 37.18% | -214.88% | 248.35% |
| Capital Expenditure | 93.77% | -449.32% | -53.15% | 66.11% | -313.73% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -56.17% | 405.09% | 112.73% | -20,421.81% | -25.39% |
| Cash from Investing | -55.07% | 403.91% | 112.37% | -8,785.33% | -107.54% |
| Total Debt Issued | -- | -- | -100.00% | 2.04% | -- |
| Total Debt Repaid | 100.00% | -- | -- | -- | -- |
| Issuance of Common Stock | 1,162.60% | 13,000.00% | 0.00% | -91.67% | -99.96% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 106.53% | -2,532,100.00% | -100.00% | 1.99% | -16.16% |
| Foreign Exchange rate Adjustments | -206.12% | 408.89% | -184.11% | 1,170.00% | 95.19% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 69.67% | -91.49% | 72.48% | -233.88% | 2,139.21% |